Earnings beat expectations, primarily due to continued recovery in customer activity across end markets, with the company achieving 5% organic growth and 13% EPS growth through strong execution.

Revenue grew 10% to $11.99B, adjusted EPS grew 13% to $6.03; organic growth of 5%, M&A contributed 5%.

Business progress: On the innovation front, launched new products such as the Orbitrap Tribrid Apex mass spectrometer; the acquired Clario and filtration and separation businesses performed well, with early signs of synergies; the PPI business system continued to improve efficiency.

Guidance and outlook: Raised full-year guidance, organic growth of approximately 4%, EPS of $24.93–$25.33 (growth of 9%–11%), with an expectation of accelerated growth in the second half of the year.

Risk/positive signals: Management tone is positive, highlighting a recovery in biopharmaceuticals and biotechnology, but the academic and government markets are only experiencing a modest recovery, and sustainability remains to be observed.